On February 7, 2013, Babich, John W.; Zimmerman, Craig; Joyal, John L.; Lu, Genliang published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of radiolabeled prostate specific membrane antigen inhibitors, particularly glutamate-urea-glutamates and glutamate-urea-lysines and their radionuclides conjugates, for diagnosis and treatment of diseases. And the patent contained the following:
The invention is related to the preparation of glutamate-urea-lysine (GUL) or glutamate-urea-glutamate (GUG) analogs in which a chelator group is conjugated to the GUL or GUG moiety via a linker, e.g., I, that are potent inhibitors of PSMA activity and to their radionuclides conjugates useful for treating or diagnosis of a disease or a condition associated with PSMA activity. Thus, I and its 111Lu-complex were prepared Biodistribution studies and affinity binding tests were conducted for the 111Lu complex. The experimental process involved the reaction of (S)-5-tert-Butyl 1-methyl 2-aminopentanedioate(cas: 53838-27-0).Category: esters-buliding-blocks
The Article related to glutamate urea lysine peptide linker radionuclide conjugate psma inhibitor, radionuclide glutamate urea homodimer conjugate preparation tracer imaging agent, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Category: esters-buliding-blocks
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics